Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Janssen win OK for Sylvant; 1st US drug in Castleman's

This article was originally published in Scrip

Executive Summary

Johnson & Johnson subsidiary Janssen gained FDA approval on 23 April for Sylvant (siltuximab), the first drug in the US to treat patients with multicentric Castleman's disease (MCD), a rare blood disorder in which lymphocytes are over-produced, leading to enlarged lymph nodes, and which also can affect the lymphoid tissue of internal organs, causing the liver, spleen or other organs to enlarge.

Advertisement

Related Content

Deal Watch: LEO Pharma Expands Market Reach Through Bayer Dermatology Deal

Topics

Advertisement
UsernamePublicRestriction

Register

SC025116

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel